Company Overview of Relypsa, Inc.
Relypsa, Inc., a pharmaceutical company, focuses on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular, and metabolic diseases in the United States. The company’s principal product candidate includes Patiromer, a non-absorbed potassium binder that completed Phase 3 clinical trial for the treatment of hyperkalemia. It also offers RLY6002, a pre-clinical product candidate that evaluates as an adjunct to diet and exercise to enhance glycemic control in adults with type 2 diabetes mellitus. The company was founded in 2007 and is headquartered in Redwood City, California.
700 Saginaw Drive
Redwood City, CA 94063
Founded in 2007
Key Executives for Relypsa, Inc.
Chief Executive Officer
Total Annual Compensation: $287.3K
Total Annual Compensation: $172.5K
Chief Medical Officer and Senior Vice President
Total Annual Compensation: $321.9K
Senior Vice President of Pharmaceutical Development & Regulatory Affairs
Total Annual Compensation: $304.0K
Senior Vice President of Pharmaceutical Operations
Total Annual Compensation: $292.0K
Compensation as of Fiscal Year 2013.
Relypsa, Inc. Key Developments
Relypsa, Inc. Announces Board Changes
Jun 19 14
Relypsa, Inc. announced the election of Daniel K. Spiegelman, executive vice president and chief financial officer of BioMarin Pharmaceutical Inc., and Kenneth J. Hillan, president and chief executive officer of Achaogen, Inc., to its board of directors following the company's annual meeting of stockholders held at June 19, 2014. Following the annual meeting of stockholders, Mr. Spiegelman was appointed chairman of the board, succeeding Dr. Scott M. Rocklage, who along with previous board members Ronald M. Hunt and Jonathan T. Silverstein did not stand for re-election. Mr. Spiegelman, age 55, is executive vice president and chief financial officer at BioMarin Pharmaceutical Inc. Dr. Hillan, M.B., Ch.B., age 53, has served as president, chief executive officer and a member of the board of directors of Achaogen, Inc., since October 2011, and as Chief Medical Officer of Achaogen since April 2011.
Relypsa, Inc. Presents at BIO International Convention, Jun-24-2014 03:45 PM
Jun 17 14
Relypsa, Inc. Presents at BIO International Convention, Jun-24-2014 03:45 PM. Venue: San Diego Convention Center, San Diego, California, United States.
Relypsa Secures Loan Facility of Up to $35 Million with Oxford Finance and Silicon Valley Bank
Jun 2 14
Relypsa, Inc. announced it has secured a loan facility of up to $35 million with Oxford Finance LLC and Silicon Valley Bank. Under the terms of the agreement, the company immediately drew $15 million upon closing on May 30, 2014, of which $11 million was used to repay in full the company's existing debt with Oxford and SVB, leaving the remaining $4 million available for working capital purposes. Payments on the new $15 million will be interest only through April 2015. Upon acceptance of the company's New Drug Application for patiromer by the U.S. Food and Drug Administration, the interest only payment period will be extended to December 2015 and the company may, at its option, draw an additional $20 million during the second half of 2015.
Similar Private Companies By Industry
Recent Private Companies Transactions
May 30, 2014